Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity

Hoppe, Charis; Holt, Derick G.; Arnold, Benjamin F.; Thinda, Sumeer; Padmanabhan, Sriranjani; Oatts, Julius T.

doi:10.1016/j.jaapos.2022.08.524

Cited by 5 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the reported refractive outcomes, we divided the studies into four categories: 1) those that revealed a lower rate of refractive error in the anti-VEGF treated eyes [20][21][22]; 2) those that revealed no significant difference in refractive outcomes between the two treatment modalities [9,16,23]; 3) those that revealed a higher rate of refractive error in the anti-VEGF treated eyes [24] or compared refractive outcomes between two anti-VEGF agents [25][26][27]; and 4) those that reported refractive outcome of sequential treatment with laser after initial anti-VEGF treatment [28,29]. Table 1 summarizes the refractive outcomes reported in the 33 primary studies.…”

Section: Resultsmentioning

confidence: 99%

“…The fourth category consisted of four papers, including 480 eyes of 260 premature infants, reporting refractive outcomes of sequential [28,29,34] or combined laser and anti-VEGF treatments [35] (Table 1). [20] 175 infants / 350 eyes Primary anti-VEGF treatment had a significantly lower incidence of amblyopia but no significant difference in the rate of myopia compared to primary laser treatment.…”

Section: Resultsmentioning

confidence: 99%

“…Infants with type 1 ROP treated with anti-VEGF and delayed laser treatments, at least 2 weeks and < 1 year after the initial anti-VEGF injection, developed lower rates of high myopia [28] compared to those with a history of laser monotherapy [28,2]. After primary anti-VEGF treatment in infants with ROP, the extents of pretreatment and pre-laser retinal vascularization were associated with the development of ≥ 1 D myopia at a mean (SD) age of 22.9 (10.9) months, without additional laser treatment [29].…”

Section: Discussionmentioning

confidence: 98%

“…Four studies were included in the fourth category concerning refractive outcomes [28,29,34,35]. Recently published studies on potential therapeutic benefits of the anti-VEGF and laser combination treatment have shown promising outcomes [29,34,35].…”

Section: Discussionmentioning

confidence: 99%

“…34 infants / 68 eyes Infants with type 1 ROP treated with the anti-VEGF and delayed laser treatments, at least 2 weeks and < 1 year after the initial anti-VEGF injection [28], developed lower rates of high myopia compared to those with a history of laser monotherapy [2].…”

Section: Hoppe Et Al (2022) [28]mentioning

confidence: 99%

See 4 more Smart Citations

Refractive outcomes in infants treated for retinopathy of prematurity

Heidary¹,

Gharebaghi²

2022

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Infants treated for retinopathy of prematurity (ROP) can develop visually significant refractive error. However, the degree of refractive error may differ between laser treatment and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection. We reviewed studies that investigated refractive error outcomes of treatment in premature infants with ROP. Methods: In this narrative review, a literature search was carried out in PubMed/MEDLINE from 01/01/2000 to 20/10/2022 without language restrictions, using the following keywords: “anti-VEGF,” “ROP” or “prematurity retinopathy,” and “laser.” We included comparative studies on refractive error outcomes of intravitreal anti-VEGF and laser treatments, a combination of both modalities simultaneously or sequentially, and two anti-VEGF agents. Results: The initial search yielded 164 records. We reviewed the titles and abstracts of the retrieved papers and the reference list of published systematic reviews and meta-analyses, meta-analyses, or reviews on our topic. Thirty-three records fulfilled our inclusion criteria, which included refractive outcomes in 4350 eyes of 2359 participants treated for ROP. Based on the reported refractive outcomes, we divided the studies into four categories: 1) those that revealed a higher rate of refractive error in the laser-treated eyes than in the anti-VEGF-treated eyes; 2) those that revealed no significant difference in refractive outcomes between the two treatment modalities; 3) those that revealed a higher rate of refractive error in the anti-VEGF-treated eyes or compared refractive outcomes between two anti-VEGF agents; and 4) those that reported refractive outcomes in the eyes that received combined simultaneous or sequential treatment with laser after initial anti-VEGF treatment. We also summarized the refractive outcomes of all included primary studies in each category. Conclusions: This study showed that the laser-treated eyes experienced more myopic shift. However, the refractive outcomes in premature infants of laser treatment, anti-VEGF treatment, and a combination of both modalities simultaneously or sequentially were often contradictory. This variability resulted from obvious differences in the sample size, different follow-up durations, or inhomogeneous study or treatment designs. Further well-designed prospective trials on refractive outcomes and the trend of changes in the refractive status over long-term follow-ups in the eyes treated with ROP are necessary to identify consensus results concerning real-world refractive outcomes of each treatment modality or simultaneous or sequential combination of both modalities, to suggest a safe and effective treatment option for eye care professionals.

show abstract